Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M DiBattiste

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Journal of Thrombosis and Thrombolysis|April 25, 2012
Effects on platelet function of a direct acting antagonist of coagulation factor XaSukit M Ringwala, Peter M Dibattiste, David J Schneider
Coronary Artery Disease|December 9, 2022
Exploring the potential cost-effectiveness of a novel platelet assay for guiding dual antiplatelet therapy duration in acute coronary syndrome patients following percutaneous coronary interventionKatherine A Vilain, Peter M DiBattiste, David J Schneider, et al.
Drugs in R&D|March 18, 2011
Cardiovascular safety profile of dapoxetine during the premarketing evaluationPeter R Kowey, Ramagopal V Mudumbi, Joseph W Aquilina, et al.
The American Journal of Cardiology|December 14, 2004
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarctionJuhana Karha, C Michael Gibson, Sabina A Murphy, et al.
Circulation|May 22, 2002
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJames L Januzzi, Steven M Snapinn, Peter M DiBattiste, et al.
International Journal of Cardiology|April 12, 2005
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS studyThao Huynh, Nicolo Piazza, Peter M DiBattiste, et al.
Archives of Drug Information|February 17, 2010
A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and PlaceboChristopher P Cannon, Cong Chen, Sean P Curtis, et al.
Journal of Thrombosis and Thrombolysis|March 4, 2005
Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry studyDeepak Talreja, Dieter Lubbe, James L Orford, et al.
Journal of the American College of Cardiology|August 18, 2004
A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarctionSaihari Sadanandan, Christopher P Cannon, C Michael Gibson, et al.
Current Medical Research and Opinion|April 8, 2021
Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databasesLu Wang, Joel N Swerdel, James Weaver, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Journal of Thrombosis and Thrombolysis|April 25, 2012
Effects on platelet function of a direct acting antagonist of coagulation factor XaSukit M Ringwala, Peter M Dibattiste, David J Schneider
Coronary Artery Disease|December 9, 2022
Exploring the potential cost-effectiveness of a novel platelet assay for guiding dual antiplatelet therapy duration in acute coronary syndrome patients following percutaneous coronary interventionKatherine A Vilain, Peter M DiBattiste, David J Schneider, et al.
Drugs in R&D|March 18, 2011
Cardiovascular safety profile of dapoxetine during the premarketing evaluationPeter R Kowey, Ramagopal V Mudumbi, Joseph W Aquilina, et al.
The American Journal of Cardiology|December 14, 2004
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarctionJuhana Karha, C Michael Gibson, Sabina A Murphy, et al.
Circulation|May 22, 2002
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJames L Januzzi, Steven M Snapinn, Peter M DiBattiste, et al.
International Journal of Cardiology|April 12, 2005
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS studyThao Huynh, Nicolo Piazza, Peter M DiBattiste, et al.
Archives of Drug Information|February 17, 2010
A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and PlaceboChristopher P Cannon, Cong Chen, Sean P Curtis, et al.
Journal of Thrombosis and Thrombolysis|March 4, 2005
Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry studyDeepak Talreja, Dieter Lubbe, James L Orford, et al.
Journal of the American College of Cardiology|August 18, 2004
A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarctionSaihari Sadanandan, Christopher P Cannon, C Michael Gibson, et al.
Current Medical Research and Opinion|April 8, 2021
Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databasesLu Wang, Joel N Swerdel, James Weaver, et al.
Pageof 5